MTOR and colorectal carcinoma: Finally, the dual PI3K/mTOR inhibitor GDC-0980 was evaluated in combination with 5-FU–based chemotherapy in advanced CRC in a phase Ib trial, and a partial response in two out of 19 patients was observed [229,230].